Harrow, Inc. Q1 2025 10-Q Filing
Ticker: HROW · Form: 10-Q · Filed: May 8, 2025 · CIK: 1360214
| Field | Detail |
|---|---|
| Company | Harrow, INC. (HROW) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, revenue, debt
TL;DR
Harrow Inc Q1 2025 10-Q filed. Sales & revenue data for Q1 2025 vs Q1 2024. Check it out.
AI Summary
Harrow, Inc. filed its 10-Q for the period ending March 31, 2025, reporting on its financial performance. The company's product sales and other revenues for the first quarter of 2025 are detailed, alongside comparative figures from the first quarter of 2024. The filing also includes information on the company's common stock and senior notes.
Why It Matters
This filing provides investors with an update on Harrow, Inc.'s financial health and operational performance for the first quarter of 2025, crucial for investment decisions.
Risk Assessment
Risk Level: medium — The filing contains financial data, including debt instruments, which inherently carry financial risks for investors.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2024-03-31 — Prior Year Quarter End Date (Provides a comparative point for the current quarter's performance.)
- 2025-01-01 — Reporting Period Start Date (Marks the beginning of the financial quarter being reported.)
- 2024-01-01 — Prior Year Quarter Start Date (Marks the beginning of the comparative financial quarter.)
Key Players & Entities
- HARROW, INC. (company) — Filer
- 0001360214 (company) — Central Index Key
- 20250331 (date) — Period of Report
- 20250508 (date) — Filed as of Date
- 615.733.4731 (dollar_amount) — Business Phone
- Harrow Health, Inc. (company) — Former Company Name
- Imprimis Pharmaceuticals, Inc. (company) — Former Company Name
- Transdel Pharmaceuticals Inc (company) — Former Company Name
- HROW:CommonStock0.001ParValuePerShareMember (company) — Equity Instrument
- HROW:Sec8.625SeniorNotesDue2026Member (company) — Debt Instrument
FAQ
What were Harrow, Inc.'s product sales for the first quarter of 2025?
The filing indicates 'HROW:ProductSalesNetMember' for the period 2025-01-01 to 2025-03-31, but the specific dollar amount is not provided in this excerpt.
How do Harrow, Inc.'s other revenues in Q1 2025 compare to Q1 2024?
The filing references 'HROW:OtherRevenuesMember' for both Q1 2025 (2025-01-01 to 2025-03-31) and Q1 2024 (2024-01-01 to 2024-03-31), but the specific figures are not detailed in this excerpt.
What is the maturity date of Harrow, Inc.'s 8.625% Senior Notes?
The filing lists 'HROW:Sec8.625SeniorNotesDue2026Member', indicating these notes are due in 2026.
What is the maturity date of Harrow, Inc.'s 11.875% Senior Notes?
The filing lists 'HROW:Sec11.875SeniorNotesDue2027Member', indicating these notes are due in 2027.
When was Harrow, Inc. previously known as Imprimis Pharmaceuticals, Inc.?
The filing states the date of name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. was 20120301.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding HARROW, INC. (HROW).